Archive: Company News
Company News: InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant Inflammation
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
The patent, entitled “Method for Modulating Responsiveness to Steroids” covers a method for enhancing steroid efficacy in steroid-refractory patients afflicted with an inflammatory condition using oligonucleotides with a specific common core sequence. It provides an exclusivity period until June 2027 with the possibility of a 3 to 5-year term extension after market approval. A corresponding European patent was granted in August 2009.
InDex Pharmaceuticals develops DIMS compounds that are synthetic oligonucleotides that function as immunomodulatory agents by targeting the Toll-like receptor 9 (TLR9). The company’s most advanced DIMS product candidate, Kappaproct, is currently in a phase III study in Europe for the treatment of chronic, active, treatment-refractory ulcerative colitis.
Company News: Nanobiotix Appoints Bernd Muehlenweg as a Member of the Executive Board
Nanobiotix has appointed Dr. Bernd Muehlenweg, currently Head of Business Development, as a member of the Executive Board in support of the future growth of Nanobiotix.
Bernd Muehlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director Business Development of oncology company WILEX AG (Munich, Germany), where he played a key role in the negotiation and execution of several license and commercialization agreements with pharma companies and in alliance management. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Pharma Licensing Club of France.
Company News: Meet akampion at Major Industry Events in April and May!
As every year, akampion will attend some key industry events and conferences. Moreover, we are very happy to contribute to the organization and preparation of two of these events: DVFA Life Science Conference and Deutsche Biotechnologietage (German Biotechnology Industry Event).
Our team will be available at the following conferences in April and May:
- Charité Summit, April 23-24 (Berlin)
- DVFA Life Science Conference, May 8 (Frankfurt)
- Deutsche Biotechnologietage, May 9-10 (Frankfurt)
- Bio€quity, May 15-16 (Frankfurt)
We are looking forward to meeting you and hope to share latest industry insights and thoughts!
Company News: InDex Pharmaceuticals Expands Management Team
– InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer –
Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas Knittel as Chief Medical Officer. Pernilla Sandwall will lead the company’s clinical development team, with the main focus being the ongoing phase III clinical trial of Kappaproct® in patients with treatment-refractory ulcerative colitis. Thomas Knittel will serve as the company’s lead medical expert and provide leadership in medical and marketing affairs.
Pernilla Sandwall has more than 20 years of experience in clinical research operations. She joins InDex Pharmaceuticals from Merck & Co. Inc. (MSD), where she has worked both in the Swedish subsidiary and the U.S. headquarters, as well as regionally in Europe. She has experience in the field as CRA and project manager, as well as strategically as Clinical Research Manager. Her focus over the last years has been global patient recruitment, site selection strategies and execution. She also has experience in change management and Lean Six Sigma methodology. She has a Master of Science in Pharmacy from Uppsala University.
Thomas Knittel has over 15 years of clinical experience within gastroenterology as well as 13 years of experience in medical affairs and marketing management. Before joining InDex Pharmaceuticals, he held positions as Business Unit Director and Director of Sales and Marketing at Novo Nordisk for central Europe, as General Manager Pharmaceuticals at Harlan Laboratories, and as Vice President Corporate and Medical Affairs at Develogen AG. He has a Medical degree from the University of Mainz with a specialist training in internal medicine and gastroenterology. He is an Associate Professor in Internal Medicine and Gastroenterology at the University Clinic Goettingen. In addition, he has an MBA from Kellogg School of Management/WHU.